- Report
- April 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- April 2025
- 200 Pages
Global
From €5707EUR$6,360USD£5,009GBP
€7134EUR$7,950USD£6,261GBP
- Report
- June 2025
- 400 Pages
Global
From €4441EUR$4,949USD£3,898GBP
- Report
- March 2025
- 99 Pages
Global
From €3500EUR$4,178USD£3,179GBP
- Report
- June 2025
- 83 Pages
United States
From €5339EUR$5,950USD£4,686GBP
- Report
- July 2025
- 155 Pages
North America
From €3096EUR$3,450USD£2,717GBP
- Report
- April 2024
- 318 Pages
Global
From €5130EUR$5,917USD£4,350GBP
- Report
- March 2024
- 200 Pages
Global
From €3724EUR$4,150USD£3,268GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €1974EUR$2,200USD£1,733GBP
€2468EUR$2,750USD£2,166GBP
- Report
- October 2021
- 288 Pages
Global
From €3230EUR$3,600USD£2,835GBP
- Drug Pipelines
- March 2023
- 125 Pages
Global
From €13456EUR$14,995USD£11,809GBP
Entyvio is a biologic drug used to treat gastrointestinal diseases such as ulcerative colitis and Crohn's disease. It is a monoclonal antibody that works by blocking a protein called integrin alpha4beta7, which is involved in the inflammatory process. Entyvio is administered intravenously and is approved for use in adults and children. It is used to reduce symptoms and improve quality of life for those suffering from gastrointestinal diseases.
Entyvio is part of a larger market of gastrointestinal drugs, which includes other biologics, immunomodulators, and corticosteroids. These drugs are used to treat a variety of gastrointestinal diseases, including inflammatory bowel disease, irritable bowel syndrome, and gastroesophageal reflux disease.
Some companies in the Entyvio market include Takeda Pharmaceuticals, Janssen Biotech, AbbVie, and Pfizer. Show Less Read more
